Literature DB >> 16219818

Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy.

Benjamin A Cohen1, Edmond A Knopp, Henry Rusinek, James S Babb, David Zagzag, Oded Gonen.   

Abstract

BACKGROUND AND
PURPOSE: Because of their invasive nature, high-grade glial tumors are uniformly fatal. The purpose of this study was to quantify MR imaging-occult, glial tumor infiltration beyond its radiologic margin through its consequent neuronal cell damage, assessed by the global concentration decline of the neuronal marker N-acetylaspartate (NAA).
METHODS: Seventeen patients (10 men; median age, 39 years; age range, 23-79 years) with radiologically suspected (later pathologically confirmed) supratentorial glial neoplasms, and 17 age- and sex-matched controls were studied. Their whole-brain NAA (WBNAA) amounts were obtained with proton MR spectroscopy: for patients on the day of surgery (n = 17), 1 day postsurgery (n = 15), and once for each control. To convert into concentrations, suitable for intersubject comparison, patients' global NAA amounts were divided by their brain volumes segmented from MR imaging. Least squares regression was used to analyze the data.
RESULTS: Pre- and postoperative WBNAA (mean +/- SD) of 9.2 +/- 2.1 and 9.7 +/- 1.8 mmol/L, respectively, in patients were indistinguishable (P = .369) but significantly lower than in controls (12.5 +/- 1.4 mmol/L). Mean resected tumor size (n = 15) was approximately 3% of total brain volume.
CONCLUSION: The average 26% WBNAA deficit in the patients, which persisted following surgical resection, cannot be explained merely by depletion within the approximately 3% MR imaging-visible tumor volume or an age-dependent effect. Although there could be several possible causes of such widespread decline--perineuronal satellitosis, neuronal deafferentation, Wallerian and retrograde degeneration, vasogenic edema, functional diaschisis, secondary vascular changes--most are a direct or indirect reflection of extensive, MR imaging-occult, microscopic tumor cell infiltration, diffusely throughout the otherwise "normal-appearing" brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219818      PMCID: PMC7976125     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  46 in total

1.  Quantitative proton MR spectroscopic imaging of the human brain.

Authors:  B J Soher; P C van Zijl; J H Duyn; P B Barker
Journal:  Magn Reson Med       Date:  1996-03       Impact factor: 4.668

2.  Hippocampal formation glucose metabolism and volume losses in MCI and AD.

Authors:  S De Santi; M J de Leon; H Rusinek; A Convit; C Y Tarshish; A Roche; W H Tsui; E Kandil; M Boppana; K Daisley; G J Wang; D Schlyer; J Fowler
Journal:  Neurobiol Aging       Date:  2001 Jul-Aug       Impact factor: 4.673

3.  Thallium-201 SPECT imaging of brain tumors: methods and results.

Authors:  K T Kim; K L Black; D Marciano; J C Mazziotta; B H Guze; S Grafton; R A Hawkins; D P Becker
Journal:  J Nucl Med       Date:  1990-06       Impact factor: 10.057

4.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms.

Authors:  P J Kelly; C Daumas-Duport; D B Kispert; B A Kall; B W Scheithauer; J J Illig
Journal:  J Neurosurg       Date:  1987-06       Impact factor: 5.115

5.  Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.

Authors:  T S Surawicz; B J McCarthy; V Kupelian; P J Jukich; J M Bruner; F G Davis
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

6.  Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens.

Authors:  C Dowling; A W Bollen; S M Noworolski; M W McDermott; N M Barbaro; M R Day; R G Henry; S M Chang; W P Dillon; S J Nelson; D B Vigneron
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

7.  Glioma cells release excitotoxic concentrations of glutamate.

Authors:  Z C Ye; H Sontheimer
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

8.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

9.  Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility.

Authors:  H J Aronen; J Glass; F S Pardo; J W Belliveau; M L Gruber; B R Buchbinder; I E Gazit; R M Linggood; A J Fischman; B R Rosen
Journal:  Acta Radiol       Date:  1995-09       Impact factor: 1.990

10.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.

Authors:  H J Aronen; I E Gazit; D N Louis; B R Buchbinder; F S Pardo; R M Weisskoff; G R Harsh; G R Cosgrove; E F Halpern; F H Hochberg
Journal:  Radiology       Date:  1994-04       Impact factor: 11.105

View more
  14 in total

1.  Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.

Authors:  U Löbel; S Hwang; A Edwards; Y Li; X Li; A Broniscer; Z Patay
Journal:  Neuroradiology       Date:  2016-07-20       Impact factor: 2.804

2.  Whole-brain N-acetylaspartate spectroscopy and diffusion tensor imaging in patients with newly diagnosed gliomas: a preliminary study.

Authors:  M Inglese; S Brown; G Johnson; M Law; E Knopp; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  Quantifying global-brain metabolite level changes with whole-head proton MR spectroscopy at 3T.

Authors:  Matthew S Davitz; William E Wu; Brian J Soher; James S Babb; Ivan I Kirov; Jeffrey Huang; Girish Fatterpekar; Oded Gonen
Journal:  Magn Reson Imaging       Date:  2016-08-28       Impact factor: 2.546

4.  Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter.

Authors:  Hatef Mehrabian; Wilfred W Lam; Sten Myrehaug; Arjun Sahgal; Greg J Stanisz
Journal:  J Neurooncol       Date:  2018-03-28       Impact factor: 4.130

5.  Association of metabolite concentrations and water diffusivity in normal appearing brain tissue with glioma grade.

Authors:  Andrew A Maudsley; Bhaswati Roy; Rakesh K Gupta; Sulaiman Sheriff; Rishi Awasthi; Meng Gu; Nuzhat Husain; Sudipa Mohakud; Sanjay Behari; Daniel M Spielman
Journal:  J Neuroimaging       Date:  2013-11-19       Impact factor: 2.486

6.  Whole brain neuronal abnormalities in focal epilepsy quantified with proton MR spectroscopy.

Authors:  Ivan I Kirov; Ruben Kuzniecky; Hoby P Hetherington; Brian J Soher; Matthew S Davitz; James S Babb; Heath R Pardoe; Jullie W Pan; Oded Gonen
Journal:  Epilepsy Res       Date:  2017-12-02       Impact factor: 3.045

7.  Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?

Authors:  Andrea Horváth; Gábor Perlaki; Arnold Tóth; Gergely Orsi; Szilvia Nagy; Tamás Dóczi; Zsolt Horváth; Péter Bogner
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130

Review 8.  Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

Authors:  D J Rigotti; M Inglese; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-05       Impact factor: 3.825

9.  Automated whole-brain N-acetylaspartate proton MRS quantification.

Authors:  Brian J Soher; William E Wu; Assaf Tal; Pippa Storey; Ke Zhang; James S Babb; Ivan I Kirov; Yvonne W Lui; Oded Gonen
Journal:  NMR Biomed       Date:  2014-09-05       Impact factor: 4.044

10.  Analysis of human gliomas by swab touch spray-mass spectrometry: applications to intraoperative assessment of surgical margins and presence of oncometabolites.

Authors:  Valentina Pirro; Raquel Sero Llor; Alan K Jarmusch; Clint M Alfaro; Aaron A Cohen-Gadol; Eyas M Hattab; R Graham Cooks
Journal:  Analyst       Date:  2017-10-23       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.